Adaptive Biotechnologies Corporation (ADPT)

SEATTLE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced Dr. Harlan Robins, Chief Scientific Officer and Co-Founder and Susan Bobulsky, Chief Commercial Officer, MRD will be participating in a Jefferies fireside chat to discuss Minimal Residual Disease (MRD) in Hematology/Oncology with deep dive into the clonoSEQ assay technology. The call will take place on Thursday, December 11, 2025, from 2:00 p.m. to 3:00 p.m. Eastern Time. Interested parties may reach out to their Jefferies sales representative for details.

SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced growing interventional use of its clonoSEQ® test among the 90 abstracts featuring clonoSEQ data at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place Dec. 6–9, 2025, in Orlando. Notably, 17 abstracts utilizing Adaptive's clonoSEQ® test exemplify how next-generation sequencing-based measurable residual disease (MRD) status is guiding clinical actions to improve blood cancer patient care.

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) stock is trading lower on Friday, despite no company-specific news, likely reacting to Natera Inc.'s (NASDAQ: NTRA) acquisition of cancer diagnostics firm Foresight Diagnostics for $275 million upfront and up to $175 million in additional earnouts tied to revenue- and reimbursement-based milestones.

SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in 89 abstracts, including 36 oral presentations, at the 67th Annual Meeting of the American Society of Hematology (ASH) taking place Dec. 6–9, 2025, in Orlando. Key highlights include: Abstracts featuring clonoSEQ MRD data span multiple myeloma (MM), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and other blood cancers, underscoring its position as the most widely used and validated next-generation sequencing-based MRD test in lymphoid malignancies.

Campbell and CO Investment Adviser LLC trimmed its position in Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 76.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 33,609 shares of the company's stock after selling 110,331 shares during the quarter. Campbell and CO

SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences. Jefferies Global Healthcare Conference in London, UKPresentation on Wednesday, November 19, 2025, at 8:00 a.m.

Adaptive Biotechnologies Corporation ( ADPT ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Karina Calzadilla - Vice President of Investor Relations Chad Robins - Co-Founder, CEO & Chairman Kyle Piskel - VP, CFO & Principal Accounting Officer Susan Bobulsky - Chief Commercial Officer of MRD Conference Call Participants Mark Massaro - BTIG, LLC, Research Division Subbu Nambi Andrew Brackmann - William Blair & Company L.L.C., Research Division Sebastian Sandler - JPMorgan Chase & Co, Research Division William Bonello David Westenberg - Piper Sandler & Co., Research Division Daniel Brennan Presentation Operator Good day, and thank you for standing by.

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.22 per share a year ago.

SEATTLE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2025. “Our third quarter results reflect another period of strong growth and financial progress,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies.

Adaptive Biotechnologies (ADPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SEATTLE, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2025 after market close on Wednesday, November 5, 2025.

Here is how Adaptive Biotechnologies (ADPT) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Chad Robins - Co-Founder, CEO & Chairman Kyle Piskel - VP, CFO & Principal Accounting Officer Conference Call Participants Yuko Oku - Morgan Stanley, Research Division Presentation Yuko Oku Equity Analyst Hi. My name is Yuko Oku, and I'm on the life science tools and diagnostics team here at Morgan Stanley.

Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out.